newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026

  • Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma Group International, was ranked No. 3 in the Small Molecules category on The Medicine Maker Power List 2026.
  • The 2026 Power List honors 60 global pharmaceutical leaders selected by industry peers & expert judges to recognize advances in drug discovery & patient access.
  • Dr. Yang co-founded Ascentage in 2009 & leads a pipeline of small molecule cancer therapies with global first- or best-in-class potential.
  • Ascentage secured China approval for lisaftoclax in July 2025 for chronic lymphocytic leukemia & small lymphocytic lymphoma, making it only the second Bcl-2 inhibitor approved worldwide since 2016.
  • Olverembatinib is the first third-generation BCR-ABL tyrosine kinase inhibitor approved in China for specific chronic myeloid leukemia (CML) patient populations.
  • The company is advancing multiple global Phase III programs for olverembatinib & lisaftoclax across hematologic cancers & solid tumors, including targeted protein degradation approaches.
  • Four of Ascentage's registrational Phase III studies have been cleared by both the U.S. FDA & the European Medicines Agency (EMA).
  • Lisaftoclax is currently the only Bcl-2 inhibitor in a global registrational Phase III study for patients with higher-risk myelodysplastic syndromes (MDS).
  • Ascentage became the first biopharmaceutical company to achieve dual primary listings by listing on the Hong Kong Stock Exchange in October 2019 & on Nasdaq in January 2025.
  • Olverembatinib & lisaftoclax are under investigation & have not yet received approval from the U.S. FDA.
  • Ascentage Pharma has established global partnerships with major companies such as Takeda, AstraZeneca, Merck, Pfizer, & Innovent.